News
Stocktwits on MSN5d
Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...
Pharmaceutical Technology on MSN5d
Regeneron to acquire rights for Hansoh’s HS-20094 therapyRegeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the clinical development and ...
Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...
Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback